⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 12, 2026Journal of Dermatological TreatmentOpen Access

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Jonathan I. Silverberg Thomas Bieber Kilian Eyerich April W. Armstrong Brian J. Nickoloff Chitra R Natalie Gaia GALLO Angela J. Okragly Eckhard Wolf Chenjia Xu Brian A. Moser María José Rueda Hany Elmaraghy Özge Uluçkan Johann E. Gudjonsson

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the maintenance of response to lebrikizumab after discontinuation in atopic dermatitis patients.
Assessing patient response to lebrikizumab after off-therapy
Monitoring for a 38-week period post-discontinuation
Analyzing subsets of patients who maintained response.
Patients exhibited sustained maintenance of response after discontinuation.
Remission lasted for at least 38 weeks in some patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Lebrikizumab demonstrates off-therapy maintenance of response in atopic dermatitis patients, suggesting longer treatment intervals may be effective.

Abstract

Lebrikizumab demonstrated off-therapy maintenance of response in an AD patient subset for at least 38 weeks post-discontinuation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Silverberg et al. (2026) studied this question.

synapsesocial.com/papers/69b4adb518185d8a39801672 https://doi.org/10.1080/09546634.2026.2636417

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis2025
2Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic DermatitisOriginal Research · 2026
3Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Original Research · 2026 · 1 citations
4Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment2024 · 15 citations
5732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations2024 · 5 citations
6Sustainability of Early Responses and Achievement of Delayed Responses to Lebrikizumab in Atopic Dermatitis: A 48-Week Japanese Real-World Study.Cohort Study · 2026
7Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trialsRCT · 2023 · 167 citations
8Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic DermatitisOriginal Research · 2026
9Disease control of atopic dermatitis in people receiving dupilumab treatment: a plain language summary of the real-world study on Atopic Dermatitis Control Tool in the Gulf countriesJournal of Dermatological Treatment · 2026
10Treatment patterns and clinical burden in adults and children with plaque psoriasis: a real-world surveyJournal of Dermatological Treatment · 2026

More from Journal of Dermatological Treatment

More from University of Michigan

More from University of California, Los Angeles

More from Ludwig-Maximilians-Universität München

More from George Washington University

More from Eli Lilly (United States)

More from University Medical Center Freiburg

More from Michigan Medicine

More from University Dermatology

More from United BioSource Corporation (United Kingdom)

More from Almirall (Spain)

More from TechSource (United States)